Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
70
ADMA Quote, Financials, Valuation and Earnings
Last price:
$20.12
Seasonality move
:
0.07%
Day range:
$19.56 - $20.22
52-week range:
$13.50 - $25.67
Dividend yield:
0%
P/E ratio:
23.62x
P/S ratio:
10.12x
P/B ratio:
11.10x
Volume:
2.7M
Avg. volume:
3.7M
1-year change:
0.8%
Market cap:
$4.8B
Revenue:
$426.5M
EPS (TTM):
$0.85
Analysts' Opinion
-
Consensus RatingADMA Biologics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $27.25, ADMA Biologics, Inc. has an estimated upside of 35.51% from its current price of $20.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $20.11.
Fair Value
-
According to the consensus of 4 analysts, ADMA Biologics, Inc. has 35.51% upside to fair value with a price target of $27.25 per share.
ADMA vs. S&P 500
-
Over the past 5 trading days, ADMA Biologics, Inc. has overperformed the S&P 500 by 4.95% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ADMA Biologics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ADMA Biologics, Inc. has grown year-over-year revenues for 26 quarters straight. In the most recent quarter ADMA Biologics, Inc. reported revenues of $134.2M.
Earnings Growth
-
ADMA Biologics, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter ADMA Biologics, Inc. reported earnings per share of $0.15.
Enterprise value:
4.8B
EV / Invested capital:
9.35x
Price / LTM sales:
10.12x
EV / EBIT:
28.79x
EV / Revenue:
9.84x
PEG ratio (5yr expected):
0.11x
EV / Free cash flow:
118.40x
Price / Operating cash flow:
121.81x
Enterprise value / EBITDA:
27.47x
Gross Profit (TTM):
$267.2M
Return On Assets:
41.45%
Net Income Margin (TTM):
42.87%
Return On Equity:
58.71%
Return On Invested Capital:
47.04%
Operating Margin:
38.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $234.3M | $382.8M | $488.6M | $119.8M | $134.2M | |
| Gross Profit | $71.3M | $186.8M | $267.2M | $59.6M | $75.6M | |
| Operating Income | $1.3M | $114.9M | $167M | $39.6M | $51M | |
| EBITDA | $9.5M | $123.1M | $175M | $41.6M | $53M | |
| Diluted EPS | -$0.11 | $0.28 | $0.85 | $0.15 | $0.15 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $174.8M | $224.1M | $273.7M | $318.2M | $402.7M | |
| Total Assets | $238.6M | $300.6M | $349M | $390.6M | $568.7M | |
| Current Liabilities | $32.3M | $44.4M | $41.8M | $44.9M | $56.5M | |
| Total Liabilities | $135.9M | $200.2M | $197.6M | $158.7M | $137.5M | |
| Total Equity | $102.8M | $100.4M | $151.4M | $231.9M | $431.2M | |
| Total Debt | $101.8M | $152M | $152M | $110.2M | $81.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.2M | $86.1M | $65M | $25M | $13.3M | |
| Cash From Investing | -$7.3M | -$7.2M | -$24.4M | -$1.1M | -$14.4M | |
| Cash From Financing | $62.7M | -$66.3M | -$65.9M | -$25.5M | -$27.8M | |
| Free Cash Flow | -$23.5M | $78.8M | $40.6M | $23.9M | -$1.1M | |
ADMA
Sector
Market Cap
$4.8B
$28.4M
Price % of 52-Week High
78.34%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
0.91%
-1.32%
1-Year Price Total Return
0.8%
-22.19%
Beta (5-Year)
0.433
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$19.29
200-day SMA
Buy
Level
$17.96
Bollinger Bands (100)
Buy
Level
14.94 - 17.96
Chaikin Money Flow
Sell
Level
-323.6M
20-day SMA
Buy
Level
$17.10
Relative Strength Index (RSI14)
Buy
Level
76.78
ADX Line
Buy
Level
33.13
Williams %R
Sell
Level
-2.2
50-day SMA
Buy
Level
$15.79
MACD (12, 26)
Buy
Level
1.20
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
498.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (17.875)
Buy
CA Score
(Annual)
Level (1.8447)
Sell
Beneish M-Score
(Annual)
Level (1.7549)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-4.4071)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
Stock Forecast FAQ
In the current month, ADMA has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADMA average analyst price target in the past 3 months is $27.25.
-
Where Will ADMA Biologics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ADMA Biologics, Inc. share price will rise to $27.25 per share over the next 12 months.
-
What Do Analysts Say About ADMA Biologics, Inc.?
Analysts are divided on their view about ADMA Biologics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ADMA Biologics, Inc. is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is ADMA Biologics, Inc.'s Price Target?
The price target for ADMA Biologics, Inc. over the next 1-year time period is forecast to be $27.25 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ADMA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ADMA Biologics, Inc. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ADMA?
You can purchase shares of ADMA Biologics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ADMA Biologics, Inc. shares.
-
What Is The ADMA Biologics, Inc. Share Price Today?
ADMA Biologics, Inc. was last trading at $20.12 per share. This represents the most recent stock quote for ADMA Biologics, Inc.. Yesterday, ADMA Biologics, Inc. closed at $20.11 per share.
-
How To Buy ADMA Biologics, Inc. Stock Online?
In order to purchase ADMA Biologics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ADMA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ADMA
Sector
P/E ratio
23.62x
23.66x
PEG ratio
0.11x
-0.01x
P/B ratio
11.10x
1.84x
Price / LTM sales
10.12x
1.60x
Growth Metrics
ADMA
Sector
Revenue growth
12%
4.85%
Earnings growth
1.5%
11.15%
Revenue (5-year growth)
70.79%
6.45%
Earnings forecast
$0.16
-$0.20
Profitability
ADMA
Sector
Profitability FY 2024
$219.2M
$3.6M
Return on invested capital
47.04%
-30.98%
Return on assets
41.45%
-27.62%
Return on equity
58.71%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
4
Balance Sheet
ADMA
Sector
Total cash
$61.4M
$27.2M
Short term investments
--
$25.7M
Total assets
$498.4M
$79.9M
Long term debt
$81.8M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
